Current Use of Hearts From Hepatitis C Viremic Donors

Yasbanoo Moayedi, Chun Po S. Fan, Aliya F. Gulamhusein, Cedric Manlhiot, Heather J. Ross, Jeffrey J. Teuteberg, Kiran K. Khush

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Strategies to improve donor heart utilization are required in the setting of limited donor availability. One innovative strategy is to consider the use of hepatitis C viremic (HCV) nucleic acid amplification test positive donors in hepatitis C-negative recipients, given the availability of highly effective direct acting antiviral agents. We utilized United Network for Organ Sharing data to evaluate the geographic distribution, clinical characteristics, and post-transplant outcomes of HCV+ donor hearts. METHODS AND RESULTS: The United Network for Organ Sharing registry was queried for all HCV+ recovered donors and those considered for heart donation classified by sex, age group, United Network for Organ Sharing region, and cause of death from January 1, 2014, to December 31, 2017. Propensity score matching (3:1) was applied to the recipients based on the index for mortality prediction after cardiac transplantation score and donor risk index. A total of 1306 HCV+ donors were recovered from 2014 to 2017 of whom 1078 (82.5%) were 18 to 49 and predominantly from the Appalachia region (United Network for Organ Sharing regions 2, 3, and 11). A total of 64 (5%) HCV+ donor hearts were transplanted in this interval. The match-adjusted risk difference in survival was estimated to be 0.87% ( P=0.83) at 12 months. CONCLUSIONS: To meet the demands of heart transplantation, we must consider additional strategies to expand the donor pool. From 2014 to 2017, despite availability of highly effective direct acting antiviral therapy, only 5% of HCV+ donor hearts were accepted for transplantation. National efforts may be required to capitalize on this resource while we continue to carefully monitor the safety of this novel approach.

Original languageEnglish (US)
Pages (from-to)e005276
JournalCirculation. Heart failure
Volume11
Issue number12
DOIs
StatePublished - Dec 1 2018
Externally publishedYes

Fingerprint

Hepatitis C
Tissue Donors
Heart Transplantation
Antiviral Agents
Appalachian Region
Nucleic Acid Amplification Techniques
Hospital Distribution Systems
Propensity Score
Information Dissemination
Registries
Cause of Death
Age Groups
Transplantation
Transplants
Safety
Survival
Mortality

Keywords

  • cause of death
  • heart transplantation
  • hepacivirus
  • hepatitis C
  • propensity score
  • survival
  • tissue donors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Moayedi, Y., Fan, C. P. S., Gulamhusein, A. F., Manlhiot, C., Ross, H. J., Teuteberg, J. J., & Khush, K. K. (2018). Current Use of Hearts From Hepatitis C Viremic Donors. Circulation. Heart failure, 11(12), e005276. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005276

Current Use of Hearts From Hepatitis C Viremic Donors. / Moayedi, Yasbanoo; Fan, Chun Po S.; Gulamhusein, Aliya F.; Manlhiot, Cedric; Ross, Heather J.; Teuteberg, Jeffrey J.; Khush, Kiran K.

In: Circulation. Heart failure, Vol. 11, No. 12, 01.12.2018, p. e005276.

Research output: Contribution to journalArticle

Moayedi, Y, Fan, CPS, Gulamhusein, AF, Manlhiot, C, Ross, HJ, Teuteberg, JJ & Khush, KK 2018, 'Current Use of Hearts From Hepatitis C Viremic Donors', Circulation. Heart failure, vol. 11, no. 12, pp. e005276. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005276
Moayedi Y, Fan CPS, Gulamhusein AF, Manlhiot C, Ross HJ, Teuteberg JJ et al. Current Use of Hearts From Hepatitis C Viremic Donors. Circulation. Heart failure. 2018 Dec 1;11(12):e005276. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005276
Moayedi, Yasbanoo ; Fan, Chun Po S. ; Gulamhusein, Aliya F. ; Manlhiot, Cedric ; Ross, Heather J. ; Teuteberg, Jeffrey J. ; Khush, Kiran K. / Current Use of Hearts From Hepatitis C Viremic Donors. In: Circulation. Heart failure. 2018 ; Vol. 11, No. 12. pp. e005276.
@article{e22d77c177d14e4f989cbdc08a73beaa,
title = "Current Use of Hearts From Hepatitis C Viremic Donors",
abstract = "BACKGROUND: Strategies to improve donor heart utilization are required in the setting of limited donor availability. One innovative strategy is to consider the use of hepatitis C viremic (HCV) nucleic acid amplification test positive donors in hepatitis C-negative recipients, given the availability of highly effective direct acting antiviral agents. We utilized United Network for Organ Sharing data to evaluate the geographic distribution, clinical characteristics, and post-transplant outcomes of HCV+ donor hearts. METHODS AND RESULTS: The United Network for Organ Sharing registry was queried for all HCV+ recovered donors and those considered for heart donation classified by sex, age group, United Network for Organ Sharing region, and cause of death from January 1, 2014, to December 31, 2017. Propensity score matching (3:1) was applied to the recipients based on the index for mortality prediction after cardiac transplantation score and donor risk index. A total of 1306 HCV+ donors were recovered from 2014 to 2017 of whom 1078 (82.5{\%}) were 18 to 49 and predominantly from the Appalachia region (United Network for Organ Sharing regions 2, 3, and 11). A total of 64 (5{\%}) HCV+ donor hearts were transplanted in this interval. The match-adjusted risk difference in survival was estimated to be 0.87{\%} ( P=0.83) at 12 months. CONCLUSIONS: To meet the demands of heart transplantation, we must consider additional strategies to expand the donor pool. From 2014 to 2017, despite availability of highly effective direct acting antiviral therapy, only 5{\%} of HCV+ donor hearts were accepted for transplantation. National efforts may be required to capitalize on this resource while we continue to carefully monitor the safety of this novel approach.",
keywords = "cause of death, heart transplantation, hepacivirus, hepatitis C, propensity score, survival, tissue donors",
author = "Yasbanoo Moayedi and Fan, {Chun Po S.} and Gulamhusein, {Aliya F.} and Cedric Manlhiot and Ross, {Heather J.} and Teuteberg, {Jeffrey J.} and Khush, {Kiran K.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1161/CIRCHEARTFAILURE.118.005276",
language = "English (US)",
volume = "11",
pages = "e005276",
journal = "Circulation: Heart Failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Current Use of Hearts From Hepatitis C Viremic Donors

AU - Moayedi, Yasbanoo

AU - Fan, Chun Po S.

AU - Gulamhusein, Aliya F.

AU - Manlhiot, Cedric

AU - Ross, Heather J.

AU - Teuteberg, Jeffrey J.

AU - Khush, Kiran K.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - BACKGROUND: Strategies to improve donor heart utilization are required in the setting of limited donor availability. One innovative strategy is to consider the use of hepatitis C viremic (HCV) nucleic acid amplification test positive donors in hepatitis C-negative recipients, given the availability of highly effective direct acting antiviral agents. We utilized United Network for Organ Sharing data to evaluate the geographic distribution, clinical characteristics, and post-transplant outcomes of HCV+ donor hearts. METHODS AND RESULTS: The United Network for Organ Sharing registry was queried for all HCV+ recovered donors and those considered for heart donation classified by sex, age group, United Network for Organ Sharing region, and cause of death from January 1, 2014, to December 31, 2017. Propensity score matching (3:1) was applied to the recipients based on the index for mortality prediction after cardiac transplantation score and donor risk index. A total of 1306 HCV+ donors were recovered from 2014 to 2017 of whom 1078 (82.5%) were 18 to 49 and predominantly from the Appalachia region (United Network for Organ Sharing regions 2, 3, and 11). A total of 64 (5%) HCV+ donor hearts were transplanted in this interval. The match-adjusted risk difference in survival was estimated to be 0.87% ( P=0.83) at 12 months. CONCLUSIONS: To meet the demands of heart transplantation, we must consider additional strategies to expand the donor pool. From 2014 to 2017, despite availability of highly effective direct acting antiviral therapy, only 5% of HCV+ donor hearts were accepted for transplantation. National efforts may be required to capitalize on this resource while we continue to carefully monitor the safety of this novel approach.

AB - BACKGROUND: Strategies to improve donor heart utilization are required in the setting of limited donor availability. One innovative strategy is to consider the use of hepatitis C viremic (HCV) nucleic acid amplification test positive donors in hepatitis C-negative recipients, given the availability of highly effective direct acting antiviral agents. We utilized United Network for Organ Sharing data to evaluate the geographic distribution, clinical characteristics, and post-transplant outcomes of HCV+ donor hearts. METHODS AND RESULTS: The United Network for Organ Sharing registry was queried for all HCV+ recovered donors and those considered for heart donation classified by sex, age group, United Network for Organ Sharing region, and cause of death from January 1, 2014, to December 31, 2017. Propensity score matching (3:1) was applied to the recipients based on the index for mortality prediction after cardiac transplantation score and donor risk index. A total of 1306 HCV+ donors were recovered from 2014 to 2017 of whom 1078 (82.5%) were 18 to 49 and predominantly from the Appalachia region (United Network for Organ Sharing regions 2, 3, and 11). A total of 64 (5%) HCV+ donor hearts were transplanted in this interval. The match-adjusted risk difference in survival was estimated to be 0.87% ( P=0.83) at 12 months. CONCLUSIONS: To meet the demands of heart transplantation, we must consider additional strategies to expand the donor pool. From 2014 to 2017, despite availability of highly effective direct acting antiviral therapy, only 5% of HCV+ donor hearts were accepted for transplantation. National efforts may be required to capitalize on this resource while we continue to carefully monitor the safety of this novel approach.

KW - cause of death

KW - heart transplantation

KW - hepacivirus

KW - hepatitis C

KW - propensity score

KW - survival

KW - tissue donors

UR - http://www.scopus.com/inward/record.url?scp=85058879446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058879446&partnerID=8YFLogxK

U2 - 10.1161/CIRCHEARTFAILURE.118.005276

DO - 10.1161/CIRCHEARTFAILURE.118.005276

M3 - Article

C2 - 30562093

AN - SCOPUS:85058879446

VL - 11

SP - e005276

JO - Circulation: Heart Failure

JF - Circulation: Heart Failure

SN - 1941-3297

IS - 12

ER -